Publication: Diabetic macular edema and ocular medical treatment options
dc.contributor.author | Olcaysu, Osman Okan | |
dc.contributor.buuauthor | Kıvanç, Sertaç Argün | |
dc.contributor.buuauthor | KIVANÇ, SERTAÇ ARGUN | |
dc.contributor.buuauthor | Budak, Berna Akova | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göz Hastalıkları Anabilim Dalı. | |
dc.contributor.orcid | 0000-0003-0995-5260 | |
dc.contributor.researcherid | AAH-6518-2021 | |
dc.contributor.researcherid | ABE-3033-2020 | |
dc.date.accessioned | 2024-10-07T13:26:19Z | |
dc.date.available | 2024-10-07T13:26:19Z | |
dc.date.issued | 2015-04-01 | |
dc.description.abstract | Diabetes mellitus (DM) is one of the most common endocrine diseases which causes serious morbidity. Damage occurs in many end organs in diabetic patients. Eyes are also among the end organs and DM causes morbidity related to diabetic retinopathy. It is estimated that 10 % of the diabetic patients have visual impairment and 2 % have blindness. Diabetic macular edema is the main cause for visual impairment in patients with diabetic retinopathy. Treatment of the DME gains importance with new treatment modalities in last decade. Ocular medical treatment modalities were discussed with the review of recent literature. | |
dc.identifier.doi | 10.4328/JCAM.3213 | |
dc.identifier.endpage | 245 | |
dc.identifier.issn | 1309-0720 | |
dc.identifier.startpage | 237 | |
dc.identifier.uri | https://doi.org/10.4328/JCAM.3213 | |
dc.identifier.uri | https://hdl.handle.net/11452/46006 | |
dc.identifier.volume | 6 | |
dc.identifier.wos | 000215587000039 | |
dc.indexed.wos | WOS.ESCI | |
dc.language.iso | en | |
dc.publisher | Derman Medical Publ | |
dc.relation.journal | Journal Of Clinical And Analytical Medicine | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.subject | Endothelial growth-factor | |
dc.subject | Intravitreal triamcinolone acetonide | |
dc.subject | Posterior subtenon injection | |
dc.subject | Randomized clinical-trial | |
dc.subject | Retina study-group | |
dc.subject | Factor trap-eye | |
dc.subject | Bevacizumab avastin | |
dc.subject | Laser treatment | |
dc.subject | Visual-acuity | |
dc.subject | Grid photocoagulation | |
dc.subject | Macular edema | |
dc.subject | Laser photocoagulation | |
dc.subject | Intravitreal injection | |
dc.subject | Vegf | |
dc.subject | Science & technology | |
dc.subject | Life sciences & biomedicine | |
dc.subject | Medicine, general & internal | |
dc.subject | General & internal medicine | |
dc.title | Diabetic macular edema and ocular medical treatment options | |
dc.type | Review | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | c34828fa-eda6-42fd-a25f-67d0b219d1bb | |
relation.isAuthorOfPublication.latestForDiscovery | c34828fa-eda6-42fd-a25f-67d0b219d1bb |